SciClone Pharmaceuticals

Executive Summary

SciClone Pharmaceuticals is a China-based biopharmaceutical company with a commercial presence in oncology, infectious diseases, and cardiovascular medicine. Its lead marketed product, Zadaxin (Thymalfasin), an immunomodulator, generates steady revenue and the company is advancing a pipeline including PT-112 for solid tumors. With a strategy that blends internal R&D and strategic partnerships, SciClone aims to address significant unmet medical needs in China and internationally. The company was founded in 2020 and is publicly listed, employing 200-500 staff. While its pipeline appears early-stage, its commercial product provides a financial base to support development efforts. In the near term, SciClone's value inflection points center on pipeline progress and potential label expansions. PT-112 is a key candidate in phase 2 for various solid tumors; top-line data or enrollment updates could catalyze investor interest. Additionally, new indications for Zadaxin or licensing deals in China may further enhance growth prospects. The company's ability to execute on its development strategy and navigate China's regulatory environment will be critical. Given the early stage of its pipeline and dependence on Zadaxin, conviction is moderate.

Upcoming Catalysts (preview)

• Q3 2026PT-112 Phase 2 interim data readout for solid tumors55% success
• Q2 2026Regulatory approval or label expansion for Zadaxin in a new indication in China70% success
• H2 2026New partnership or licensing agreement for pipeline candidates50% success